Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Authors:
- 28 July 2021
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 39 (6) , 1641-1648
Abstract
Summary Background The phosphatidylinositol-3 kinase pathway is often altered in head and neck squamous cell carcinoma (HNSCC), and is involved in the resistance to EGFR inhibitors. Objective We investigated the dose-limiting toxicities (DLTs), maximum tolerated dose, pharmacokinetics, and preliminary efficacy of the combination of copanlisib, an intravenous, pan-class I PI3K inhibitor, with the anti-EGFR monoclonal antibody cetuximab in recurrent and/or metastatic HNSCC patients in a phase I dose-escalation trial. Patients and methods Copanlisib was given intravenously on days 1, 8, and 15 of 28-day cycles at the dose of 45 mg and 30 mg, in combination with standard doses of weekly cetuximab (400 mg/m2 loading dose followed by 250 mg/m2 on days 8, 15, and 22, and weekly thereafter). Results Three patients received copanlisib 45 mg, of whom two experienced grade 3 hyperglycemia during Cycle 1 that met the DLT criteria. Eight patients were then treated with copanlisib at the dose of 30 mg. Because of the occurrence of hyperglycemia, a premedication with metformine was introduced on the day of the injections. No DLTs were reported at this dose level. The trial was stopped early because of the unfavourable toxicity profile of the combination. Among eight evaluable patients for response, four patients (50%) had disease stabilization according to RECIST1.1 as best response. Conclusion Copanlisib combined with cetuximab demonstrated unfavorable toxicity and limited efficacy in heavily pretreated recurrent and/or metastatic HNSCC patients. Trial registration NCT02822482, Date of registration: June 2016.Keywords
All Related Versions
This publication has 17 references indexed in Scilit:
- Comprehensive genomic characterization of head and neck squamous cell carcinomasNature, 2015
- A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancerAnnals of Oncology, 2014
- Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphomaBlood, 2014
- The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer modelsBritish Journal of Cancer, 2014
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent LymphomaNew England Journal of Medicine, 2014
- Evaluation of comorbidity in 9388 head and neck cancer patients: A national cohort study from the DAHANCA databaseRadiotherapy and Oncology, 2014
- Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive BiomarkersCancer Discovery, 2013
- Mechanisms underlying resistance to cetuximab in the HNSCC cell line: Role of AKT inhibition in bypassing this resistanceInternational Journal of Oncology, 2010
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006